StockData

Calumet vs Delek US

CLMT and DK side by side, both in petroleum refining. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLMT and DK compare

Delek US is the larger company, worth 1.3 times as much as Calumet ($4.1B against $3.2B).

Calumet grew revenue faster over the last twelve months (28.4% versus 27.1% for Delek US).

Delek US keeps more of each dollar of sales as profit, with a net margin of 8.7% compared with −3.7% at Calumet.

Delek US pays a dividend yielding 1.1%; Calumet does not pay one.

Delek US scores higher on the StockData Score (14 against 3 for Calumet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLMTDK
Size and price
Market cap$3.2B$4.1B
Share price$35.89$67.16
Change, 1 year87.4%61.8%
Change, 5 years152%334%
Beta (5Y)0.870.51
Employees1,5401,902
StockData Score
Total score314 (better)
Valuation score05 (better)
Growth score22
Performance score02 (better)
Health score12 (better)
Dividend score03 (better)
Valuation
P/E–3.6×
P/S0.6×0.3× (better)
EV/EBITDA15.1×2.9× (better)
P/FCF11.9×3.4× (better)
FCF yield8.4%29.2% (better)
Fair value–$240.46
Margin of safety–72.1%
Growth
Revenue growth (TTM)28.4% (better)27.1%
Revenue growth, 5Y average12.8% (better)8.0%
Profitability
Gross margin9.1%15.0% (better)
Operating margin3.4%13.3% (better)
Net margin−3.7%8.7% (better)
FCF margin5.1%8.9% (better)
Return on invested capital9.8%–
Financial health
Net debt / EBITDA5.780.92 (better)
Interest coverage0.9×–
Current ratio1.061.33 (better)
Altman Z-score1.682.90 (better)
Piotroski F-score55
Dividends and buybacks
Dividend yield–1.1%
Payout ratio–5.3%
Years of dividend growth–4
Dividend growth, 5Y average–1.9%
Shareholder yield0.00%1.1% (better)
Ownership
Held by institutions52.4%101%
Held by insiders20.5%2.4%
Insider net buying, 12 months−$20.7M (better)−$46.5M
Short interest, % of float6.3%12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.